// App-Quantinova.ai

518 : Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441).

Researchers

Presenter

  • Pascal Hammel

Principal Investigators

  • Teresa Macarulla

  • Rocio Garcia-Carbonero

  • Jean-Philippe Metges

  • Olivier Bouch

  • Fabienne Portales

  • Roberto A. Pazo Cid

  • Laurent Mineur

  • Antonio Manuel Cubillo Gracian

  • Isabelle Trouilloud

  • Rosine Guimbaud

  • David Tougeron

  • Juan Jose Reina Zoilo

  • Jaime Feliu

  • Tamara Sauri

  • Christos Fountzilas

  • Richard Kay

  • Hagop Youssoufian

  • Manuel Hidalgo

Medical Centers

  • Hopital Beaujon (AP-HP), Clichy, and University Paris VII, Paris, France

  • Erytech Pharma, Cambridge, MA

  • Hospital Universitario del Mar, Barcelona, Spain

  • Oncology Department, Hospital Universitario 12 de Octubre, IIS Imas12, UCM, Madrid, Spain

  • CHU Brest–Institut de Cancerologie et d’Hematologie ARPEGO Network, Brest, France

  • CHU Robert Debre, Reims, France

  • CRLC Val d'Aurelle, Montpellier, France

  • Miguel Servet University Hospital. Aragon Institute of Health Sciences (IACS), Zaragoza, Spain

  • Institut Sainte Catherine, Avignon, France

  • Centro Intengral Oncologico Clara campal, Madrid, Spain

  • Hospital Saint Antoine, Paris, France

  • CHU Toulouse, Toulouse, France

  • Department of Gastroenterology, Poitiers University Hospital, Poitiers, France

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • Hospital Universitario La Paz, Madrid, Spain

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Roswell Park Comprehensive Cancer Center, Buffalo, NY

  • School of Pharmacy and Pharmaceutical Medicine, Wales, United Kingdom

  • Erytech contractor, Boston, MA

  • Weill Cornell Medicine, New York, NY

Locations

  • France

  • United States

  • Spain

  • United Kingdom

Companies

  • Erytech Pharma Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreatic cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Fluorouracil

  • Adrucil injection

  • Gemcitabine

  • Irinotecan

  • Paclitaxel

  • ERY001

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • NCT03665441

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved